The global challenge of HIV/AIDS remains one of the most pressing public health issues today. According to the latest data from UNAIDS, around 38.4 million people worldwide are living with HIV/AIDS, underlining the need for not only medical intervention but also comprehensive awareness, education, and social change. Despite the significant strides made in treatment and prevention, the confusion surrounding the relationship between HIV and AIDS still persists.

Young people have become influential advocates in the fight against HIV/AIDS. Research from UNICEF shows that youth-led initiatives can lower HIV transmission rates by as much as 45% in targeted communities. These young activists utilize digital platforms and peer-to-peer education to dispel myths, promote safe practices, and foster supportive environments for those affected by HIV/AIDS.

Dr Gowri Kulkarni, an expert in Internal Medicine, explains that while the terms HIV and AIDS are often used interchangeably, they are distinctly different. "HIV (Human Immunodeficiency Virus) is a virus that attacks the immune system, whereas AIDS (Acquired Immunodeficiency Syndrome) is a condition that occurs when HIV severely damages the immune system," she clarifies. To understand the implications of these differences, it's important to explore the fundamental distinctions between the two.

1. HIV is a Virus; AIDS is a Syndrome

HIV is the virus responsible for attacking the body’s immune system, specifically targeting CD4 cells, which are crucial for the body’s defense against infections. As HIV progresses, it destroys these cells, weakening the immune system over time. If left untreated, this continuous damage can lead to AIDS.

AIDS, on the other hand, is a syndrome, not a virus. Dr Kulkarni further elaborates that AIDS is a collection of symptoms and illnesses that emerge when the immune system is severely compromised due to prolonged HIV infection. It represents the most advanced stage of HIV, and is characterized by very low CD4 counts or the onset of opportunistic infections like tuberculosis, pneumonia, or certain cancers.

2. Not Everyone with HIV Develops AIDS

A key distinction to remember is that not everyone with HIV will progress to AIDS. Thanks to advancements in medicine, particularly antiretroviral therapy (ART), individuals living with HIV can manage the virus and maintain a healthy immune system for many years, or even decades, without ever developing AIDS. ART works by suppressing the virus to undetectable levels, effectively preventing the damage HIV would otherwise cause to the immune system.

Without treatment, however, HIV progresses through three stages:

- Acute HIV Infection: This stage occurs shortly after transmission and may include symptoms like fever, fatigue, and swollen lymph nodes.

- Chronic HIV Infection: Often asymptomatic or mildly symptomatic, the virus continues to damage the immune system but at a slower rate.

- AIDS: This is the final stage, marked by severe immune damage and the presence of infections that take advantage of the compromised immune defenses.

3. HIV is Transmissible; AIDS is Not

Another key distinction between HIV and AIDS is the way in which they are transmitted. HIV is highly contagious and can be transmitted through the exchange of bodily fluids such as blood, semen, vaginal fluids, and breast milk. It is primarily spread through unprotected sexual contact, sharing needles, or from mother to child during childbirth or breastfeeding.

AIDS, however, is not transmissible. It is not a disease that can be passed from one person to another. Rather, AIDS is the result of untreated, advanced HIV infection and is a direct consequence of the virus’s damage to the immune system.

4. Diagnosis Methods Differ

HIV and AIDS are diagnosed through different methods. HIV is diagnosed through blood tests or oral swabs that detect the presence of the virus or antibodies produced by the immune system in response to the virus. Early detection of HIV is crucial, as it allows for timely intervention and treatment, which can prevent the virus from progressing to AIDS.

AIDS, on the other hand, is diagnosed using more specific criteria. Dr Kulkarni notes that the diagnosis of AIDS is made when the individual’s CD4 cell count falls below 200 cells/mm³, or when opportunistic infections or certain cancers (such as Kaposi's sarcoma or lymphoma) are detected. Diagnosing AIDS involves a more thorough assessment of the individual’s immune function and overall health, as opposed to just the detection of HIV.

5. Treatment Goals Are Different

The treatment goals for HIV and AIDS differ significantly, although both involve antiretroviral therapy (ART). For HIV, the primary treatment goal is to suppress the virus to undetectable levels, thus maintaining a strong immune system and preventing further transmission of the virus. People living with HIV can often live long, healthy lives if they adhere to ART.

For individuals diagnosed with AIDS, the treatment plan becomes more complex. While ART remains an essential part of managing the virus, treatment for AIDS also focuses on addressing the opportunistic infections and secondary health complications associated with severe immune suppression. The goal of treatment for AIDS is not only to manage the HIV virus but also to improve the quality of life and extend survival by treating these secondary health issues.

Role of Community Engagement in Combatting HIV/AIDS

While the medical community has made great strides in managing HIV, the battle to curb its transmission is also a social and cultural issue. Dr Daman Ahuja, a public health expert, highlights that HIV/AIDS awareness and education are vital to reducing transmission rates and supporting those affected by the virus. "Young people, especially, have become key advocates in the fight against HIV/AIDS," says Dr Ahuja. "Research from UNICEF shows that youth-led initiatives can lower HIV transmission rates by as much as 45% in targeted communities."

Additionally, grassroots activism plays a significant role in raising awareness and addressing stigma. As the World Health Organization reports, community-based interventions have been proven to increase HIV testing rates and improve treatment adherence, which are crucial in the fight against the pandemic.

The ultimate goal of organizations like UNAIDS is to eliminate the HIV/AIDS pandemic by 2030. Achieving this requires global collaboration, from medical treatment advancements to public health strategies, education, and advocacy. Dr Kulkarni’s insight underscores the importance of early detection, treatment adherence, and community support in the fight against HIV/AIDS.

Dr Gowri Kulkarni is Head of Medical Operations at MediBuddy and Dr Daman Ahuja, a public health expert and has been associated with Red Ribbon Express Project of NACO between 2007-12.

Rare diseases may be individually uncommon, but together they represent a large and persistent care gap. More than 300 million people globally live with a rare condition, and when families and caregivers are counted, the impact touches over one billion lives. The economic burden is estimated to exceed $7 trillion each year.

In India, the challenge is compounded by geography, uneven specialist availability and the lifelong nature of many rare conditions. The question is no longer whether the system recognises the need, but whether it can deliver continuous care at scale.

Why Patients Still Struggle To Reach Care

For most rare disease patients, the hardest part is not always the science but the pathway to care. Diagnosis is often delayed, sometimes by years. Patients move between providers carrying incomplete records. Specialist centres are concentrated in a few large cities, forcing families to travel repeatedly for consultations that may last only minutes. This is both financially draining and clinically inefficient.

Telemedicine is beginning to ease some of this pressure. Virtual consultations allow specialists to extend their reach beyond metropolitan clusters. For families in tier two and tier three locations, this can mean earlier clinical input and fewer avoidable journeys.

Remote monitoring tools are also shifting care from episodic hospital visits to continuous oversight, which is particularly valuable for conditions that require close tracking over time.

Why Data Matters More Than Ever

If access is the visible challenge, data fragmentation is the structural one. Rare disease information remains scattered across hospitals, laboratories and individual case files. This weak visibility affects everything from prevalence estimates to therapy development. Policymakers struggle to size the problem accurately. Clinicians miss longitudinal patterns. Industry investment becomes harder to justify.

Digital health systems can address this by creating longitudinal patient records that follow individuals across providers. Even relatively modest steps such as strengthening diagnostic reporting or building disease registries can significantly improve coordination. For rare diseases, where patient numbers are small and widely dispersed, structured data is not a luxury. It is the backbone of effective care.

India’s Digital Opportunity

India has begun building the rails needed for this transition. The Ayushman Bharat Digital Mission is creating a national health data architecture anchored in unique health IDs and interoperable records. If applied rigorously to rare diseases, this infrastructure can support lifelong patient tracking, improve referral accuracy and give policymakers clearer visibility into disease burden.

Interoperability will determine how far this effort goes. The growing adoption of FHIR standards and API led systems is slowly allowing previously disconnected hospital platforms to exchange clinical information. For rare disease patients, whose care often spans multiple providers and years of follow up, this continuity is not technical detail. It is essential to safe treatment.

AI Moves From Promise To Practice

Artificial intelligence is also starting to show practical value. Globally, AI based clinical decision support tools are being used to flag potential rare disease cases hidden within routine health records. This matters because many rare conditions present with non specific symptoms and are frequently missed in early stages.

Collaborations between technology firms and pharmaceutical companies are demonstrating how electronic health record analysis, suspect patient lists and longitudinal data can help clinicians triage cases earlier for confirmatory testing. As these tools mature and integrate into routine workflows, they could significantly shorten the diagnostic odyssey that rare disease families currently endure.

Engaging Patients Beyond The Clinic

At the patient level, the shift is becoming more practical and visible. Tools that let people log symptoms, get medication reminders and share updates in real time are helping them stay more consistent with treatment, while giving clinicians better insight between visits. For lifelong conditions, this kind of day to day support brings care into the flow of everyday life, where most disease management actually happens.

Federated data models add an important layer of trust. By enabling analysis across multiple small patient populations without moving sensitive personal data, they address both privacy concerns and the sample size limitations that have historically slowed rare disease research.

From Pilots to Systems

Progress is visible across both public and private sectors. Regulated digital health platforms are already supporting rare disease programmes in several countries. Industry collaborations are using AI to detect conditions that often go undiagnosed for years. Public genomic databases are generating new diagnoses by enabling experts to build on shared evidence.

India’s immediate task is to move beyond isolated pilots. Telemedicine networks must be tied to referral protocols and reimbursement pathways. Digital registries must be built with strong governance and patient trust. AI tools need to be embedded into everyday clinical workflows rather than remaining demonstration projects.

Why Investment Makes Fiscal Sense

Poorly managed rare diseases create avoidable hospitalisations, lost productivity and long term care costs. Evidence increasingly shows that targeted investments in data systems, screening and coordinated care can reduce downstream expenditure. For low- and middle-income countries working within tight health budgets, these are not marginal gains.

India already has many of the building blocks needed to improve rare disease care, from expanding digital health infrastructure to growing AI capabilities and increasing policy focus. The real test now is disciplined execution.

Telemedicine networks must deepen their reach, patient registries need to become reliable and usable, data must move securely across systems, and clinicians should have decision support tools that fit into everyday practice. Taken together, these steps can meaningfully narrow today’s access gaps.

Digital health will not make rare diseases any less complex. But if implemented thoughtfully, it can reduce distance, shorten delays and bring much needed continuity to care journeys that are currently fragmented. For families managing lifelong conditions, that would be a tangible and much overdue shift.

In India, it is not uncommon for families to travel across cities, sometimes across states, seeking answers for symptoms that simply don’t make sense. A child who is not meeting developmental milestones. A young adult with unexplained muscle weakness. Recurrent hospital visits with no clear diagnosis.

For many, this long and frustrating search for clarity is what medicine calls the diagnostic odyssey.

Rare diseases are individually uncommon, but collectively they affect millions of people worldwide. Rare diseases affect an estimated 263–446 million people worldwide, spanning every geography, healthcare system, and socioeconomic context. India alone is estimated to have 70 million people living with rare diseases.

Importantly, although 70%–80% of rare diseases are genetic in origin, routine medical practices often consider genetic testing only after years of inconclusive evaluations.

In India, this challenge is amplified by several factors, including limited awareness of rare conditions, uneven access to specialized testing across regions, and a tendency to treat symptoms individually rather than look for a unifying cause.

A child may see a neurologist for seizures, a gastroenterologist for feeding issues, and a developmental pediatrician for delays, without anyone connecting the dots.

Studies have shown that patients and their families frequently wait years before receiving a confirmed diagnosis. Globally, rare disease diagnosis can take anywhere between 5–30 years.

In a country like India, where healthcare expenses are often paid out-of-pocket, this prolonged uncertainty can be devastating. Beyond cost, there is the psychological toll; parents wondering if they missed something and adult patients often questioning whether their symptoms are “all in their head”. During this period, families undergo repeated tests, face conflicting opinions, and bear significant emotional and financial strains.

Research shows that families experience profound emotional burden during the diagnostic odyssey, including stress, anxiety, and feelings of isolation.

Why Do These Conditions Stay Undetected For Years?

In many cases, the explanation is written into a person’s DNA. Genetic disorders rarely announce themselves clearly; instead, they often mimic common illnesses. Fatigue may look like anemia, developmental delay may resemble a learning difficulty, and repeated infections might be treated as isolated events rather than part of a larger pattern. Because the symptoms overlap with more familiar conditions, doctors naturally begin by treating what appears most likely.

Most healthcare systems also follow a step-by-step diagnostic approach; rule out the common causes first, then move to less common ones if symptoms persist. While this method works well for typical illnesses, it can significantly delay answers for rare genetic conditions. Without looking directly at the genetic blueprint, the underlying cause may remain hidden, even as the visible symptoms are managed one at a time.

Today, advances in genomic technologies such as whole-exome sequencing (WES) and whole-genome sequencing (WGS) allow us to examine thousands of genes simultaneously. Rather than guessing which gene might be responsible, we can comprehensively analyze a patient’s DNA to search for answers.

Evidence increasingly supports the use of genomic sequencing earlier in the diagnosis and care of rare diseases. Similarly, studies highlight how genomic testing not only provides diagnoses but also directly influences treatment decisions and long-term care planning.

In the Indian context, integrating genetic testing earlier could transform care. Instead of years of fragmented consultations, patients could receive a precise diagnosis sooner. This clarity can:

• Prevent unnecessary or repeated investigations
• Guide appropriate treatment strategies
• Inform family members about potential risks
• Enable informed decisions about future pregnancies
• Equally important, it replaces uncertainty with understanding.

Encouragingly, awareness around rare diseases is growing in India, and conversations around early genomic testing are becoming more mainstream. As technology becomes more affordable and accessible, we have an opportunity to fundamentally change the patient journey.

No family should spend years searching for answers when science has the tools to help. By embracing genomic medicine earlier in the diagnostic pathway, we can shorten the odyssey, reduce suffering, and empower families with clarity.

Because when symptoms don’t add up, sometimes the answer lies written in our genes.

Former US president Bill Clinton’s recent public appearance has sparked inquires of Parkinson’s disease in the media. The video was made public by the GOP-led House Oversight Committee, and it showed Clinton alongside his legal team giving his testimony concerning his past associations with the late convicted sex offender Jeffery Epstein.

Social media users quickly pointed out that during the video, the former president’s hand visibly trembled as he raised his glass of water. Hand tremors are often associated with cognitive decline, as it is known as an early sign of Parkinson’s.

The footage, captured at his home in Chappaqua, New York, showed a specific moment where Clinton’s hands shook as Representative Nancy Mace questioned him.

Are Hand Tremors A Sign Of Parkinson’s?

According to Parkinson’s Foundation, for many, a tremor (shaking) is the first sign of Parkinson’s. The most common type is a "resting tremor." This means your hand or leg might shake while you are sitting still or walking, but the shaking usually stops or gets better when you actually use that body part like reaching out to grab a glass of water.

Most people with Parkinson’s (70% to 90%) will have a tremor at some point. Interestingly, patients who have a resting tremor often see their symptoms progress more slowly than those who don't.

Could Hand Tremors Indicate Other Issues?

WashU Medicine explains that essential tremor is the most common reason for shaky hands, but it’s different from Parkinson’s. With essential tremors, your hands shake while you are using them, like holding a deck of cards. Parkinson’s usually causes shaking only when hands are resting. So what are some factors that can cause hand tremors?

Lifestyle and Stress

Almost everyone has a tiny, invisible tremor. However, things like high stress, being very tired, or feeling angry can make that shake visible. Drinking too much caffeine or smoking cigarettes can also cause your hands to tremble temporarily until the stimulants leave.

Age

While anyone can develop a tremor, it is most common in people over age 65. This type of shaking is usually "benign," meaning it isn't dangerous. It mostly affects the hands, head, or voice, and rarely spreads to the legs or feet.

Medication Side Effects and Withdrawal

Sometimes, the medicine you take for other things is the culprit. Drugs for asthma, seizures, or depression can cause shakiness. Shaking can also happen if you are going through alcohol withdrawal or using tobacco, as these substances directly affect your nervous system.

Potential Underlying Health Conditions

Hand tremors can sometimes be a "warning light" for other health issues. Problems like an overactive thyroid, or rare conditions where copper builds up in the body, can cause shaking. A doctor can run simple tests to see if these are the cause.

Clinton’s History with "Aging Tremors"

While the footage may appear concerning to new viewers, these tremors are a documented part of Clinton's health history. As far back as 2013, the 42nd President addressed similar concerns, clarifying that he had undergone medical testing to rule out Parkinson’s.

At the time, Clinton explained that his doctors attributed the shaking to a "normal aging phenomenon." He noted that while he was initially concerned enough to seek a professional diagnosis, he felt relieved to learn the tremors were not related to a progressive disease.